BioMark Diagnostics Inc C.BUX

Alternate Symbol(s): BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

CSE:BUX - Post by User

BioMark Diagnostics Inc

Bullboard Posts

Post by purseon Oct 27, 2016 2:27pm

140 Views

Post# 25394048

All is well

After talking with the company it sounds like all is well. Everything fully intact and they are not promoting the company because of health Canada. It all takes time, it sounds like they have an amazing discovery and on top of that insiders own 78% of the company with no selling.

Bullboard Posts

Sirios Resource discovers visible gold in Quebec